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Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), deﬁned as posttherapy persistence of leukemic cells at levels below morphologic
detection, is a strong, independent prognostic marker of increased risk of relapse and
shorter survival in patients with acute myeloid leukemia (AML) and can be used to reﬁne
risk-stratiﬁcation and treatment response assessment. Because of the association between
MRD and relapse risk, it has been postulated that testing for MRD posttreatment may help
guide postremission treatment strategies by identifying high-risk patients whomight beneﬁt
from preemptive treatment. This strategy, which remains to be formally tested, may be
particularly attractive with availability of agents that could be used to speciﬁcally eradicate
MRD. This review examines current methods of MRD detection, challenges to adopting MRD
testing in routine clinical practice, and recent recommendations for MRD testing in AML
issued by the European LeukemiaNet MRDWorking Party. Inclusion of MRD as an end point
in future randomized clinical trials will provide the data needed to move toward
standardizing MRD assays and may provide a more accurate assessment of therapeutic
eﬃcacy than current morphologic measures.
Introduction
More than 50% of adult patients with acute myeloid leukemia (AML) relapse after attaining morphologically
defined complete remission (CR) with induction chemotherapy.1-3 Assessment of posttreatment remission
is traditionally based primarily on cytomorphology, with AML relapse conventionally defined as$5% blasts
in the bone marrow not attributable to other causes.4-6 Microscopic assessment of bone marrow or
peripheral blood morphology relies on examination of a relatively small number of cells (200-500) and its
reliability is dependent, in part, on sample quality and the pathologist’s expertise.7 As primarily derived from
data in younger adults, the risk of relapse following allogeneic hematopoietic stem cell transplantation (allo-
HSCT) for consolidation after first CR is 15% to 20% for patients with favorable-risk disease, 20% to 25%
for intermediate-risk disease, 30% to 40% for poor-risk disease, and 40% to 50% for very poor-risk
disease.8 Among older patients (age $60 years) with AML, the respective pooled 2- and 5-year survival
estimates following allo-HSCT are 44% and 35% for relapse-free survival (RFS) and 45% and 38% for
overall survival (OS).9
Currently, pretreatment factors such as age, cytogenetics, and the presence of certain gene mutations
are used to estimate posttreatment risk of relapse based on data from large patient cohorts.5,6,10-12
Table 1 lists prognostic implications of specific mutations in AML as described by the European
LeukemiaNet (ELN)10 and the National Comprehensive Cancer Network guidelines.6 The risk of relapse
has been linked to the postchemotherapy persistence of “minimal residual disease” (MRD), which has
been defined as leukemic cells at levels below morphologic detection.12 Flow cytometric and molecular
techniques for assessment of residual leukemia are more sensitive than morphologic assessment, and
consensus is growing that MRD might more aptly be called “measurable residual disease,” because the
Submitted 17 January 2018; accepted 23 April 2018. DOI 10.1182/
bloodadvances.2018016378.
© 2018 by The American Society of Hematology
1356 12 JUNE 2018 x VOLUME 2, NUMBER 11
presence of any disease detected by these methodologies after
treatment is associated with a worse prognosis13,14 and detectable
leukemia even in morphologic remission may not be “minimal.”MRD
monitoring has become part of routine clinical practice in the
management of patients with acute lymphoblastic leukemia, acute
promyelocytic leukemia (APL), and chronic myeloid leukemia.15-18
Mounting evidence indicates that the presence of MRD is a strong,
independent prognostic marker of increased risk of relapse and
shorter survival in patients with AML compared with patients with a
negative MRD test.4,19-23 This recurrent observation has raised
interest in routine MRD testing in AML. To guide the development of
a standardized or harmonized approach to MRD testing, the ELN
MRD Working Party recently issued consensus recommendations
for the measurement and application of MRD in AML (Table 2).24
A prominent strategy to detect MRD is immunophenotypic
evaluation by multiparameter flow cytometry (MFC). It is now
well established that MRD detected by MFC is an independent
prognostic factor for relapse, RFS, and OS.4,19-22 In studies of
patients ,65 years of age with AML who were fit to receive
cytosine arabinoside plus anthracycline-based induction and
consolidation chemotherapy, MRD-negative status as detected by
MFC was identified as the most important independent predictor of
RFS and OS.25,26 Similarly, a retrospective exploratory analysis of
data from the Southwest Oncology Group S0106 study showed that
MFC-detected MRD after completion of induction chemotherapy
could be used to stratify younger patients by risk of AML recurrence,
and that MRD status was the single most important predictor of OS
and RFS in individual patients.27 Data in older patients with AML have
also demonstrated the prognostic relevance of MRD monitoring by
MFC in patients undergoing traditional cytotoxic chemotherapy
induction.28 Detection of MRD by MFC during morphological CR
before allo-HSCT has also been linked to a substantially higher
likelihood of relapse andworse survival.29,30 Molecular approaches to
detect MRD are equally informative for prognosis. For example,
among patients with nucleophosmin 1 (NPM1)–mutated AML who
had undergone intensive chemotherapy, the persistence of NPM1-
mutated transcripts detected using real-time polymerase chain
reaction (RT-PCR) was an independent predictor of relapse or
Table 1. Risk status stratification by genetic abnormality per ELN 2017 and NCCN 2017 guidelines
Risk category* ELN criteria10 NCCN criteria6
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Core binding factor: inv(16)†,‡ or t(16;16)†,‡ or t(8;21)†,‡ or t(15;17)‡
inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Normal cytogenetics:NPM1mutation in absence of FLT3-ITD or isolated
biallelic (double) CEBPA mutation
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow§
Biallelic mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh§ Normal cytogenetics
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow§ (without adverse-risk
genetic lesions)
18 alone
t(9;11)(p21.3;q23.3); MLLT3-KMT2A|| t(9;11)
Cytogenetic abnormalities not classified as favorable or adverse Other nondefined
Core binding factor with KIT mutation
Poor/adverse t(6;9)(p23;q34.1); DEK-NUP214 Complex ($3 clonal chromosomal abnormalities)
t(v;11q23.3); KMT2A rearranged Monosomal karyotype
t(9;22)(q34.1;q11.2); BCR-ABL1 25, 5q–, –7, 7q–
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 11q23 – non t(9;11)
25 or del(5q); –7; –17/abn(17p) inv(3), t(3;3)
Complex karyotype,{ monosomal karyotype# t(6;9)
Wild-type NPM1 and FLT3-ITDhigh t(9;22)
Mutated RUNX1** Normal cytogenetics: with FLT3-ITD mutation††
Mutated ASXL1** TP53 mutation
Mutated TP53‡‡
*The prognostic value of a marker is treatment-dependent and may change with new therapies.
†Presence of KIT mutations in patients with t(8:21) and, to a lesser extent, inv(16), confers a high risk of relapse; these patients should be considered intermediate risk and considered for
HSCT if available.
‡Other cytogenetic findings in addition to these do not alter risk status.
§Low, low allelic ratio (,0.5); high, high allelic ratio ($0.5); recent studies indicate that AML with NPM1 mutation and FLT3-ITD low allelic ratio may also have a more favorable prognosis
and patients should not routinely be assigned to allogeneic HCT.75,76
||Presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.
{3 or more chromosomal abnormalities in the absence of 1 of the World Health Organization–designated recurring translocations or inversions: t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)
(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1.
#Defined by the presence of 1 single monosomy (excluding loss of X or Y) with at least 1 additional monosomy or structural chromosome abnormality (excluding core-binding factor AML).
**These should not be used as adverse prognostic markers if they occur with favorable-risk AML subtypes.
††FLT3-ITD mutations are considered to confer a significantly poorer outcome in patients with normal karyotype; there is controversy about whether FLT3-TKD mutations carry equally poor
prognosis.
‡‡TP53 mutations are significantly associated with AML with complex and monosomal karyotype.
NCCN, National Comprehensive Cancer Network.
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Table 2. ELN recommendations for MRD testing
Recommendations
Flow cytometry
1 Use the following markers in a MRD panel:
CD7, CD11b, CD13, CD15, CD19, CD33, CD34, CD45, CD56, CD117, HLA-DR (backbone: CD45, CD34, CD117, CD13, CD33, FSC/SSC).
If necessary, add a “monocytic tube” containing:
CD64/CD11b/CD14/CD4/CD34/HLA-DR/CD33/CD45.
2 Integrate the classic LAIP approach with the DfN approach. To trace all aberrancies (at and beyond diagnosis, including newly formed postdiagnosis
aberrancies), apply a full panel both at diagnosis and follow-up.
3 Aspirate 5-10 mL BM and use the first pull for MRD assessment. At present PB, with its lower MRD content, should not be used for MRD assessment.
Pull as low as desirable BM volume because contamination with PB increases with BM volume.
4 Estimate the contamination with PB, especially when a first pool of BM was impossible.
5 Use 500 000 to 1 000 000 white blood cells, use the best aberrancy available and relate it to CD451 white blood cells.
6 To define “MRD-negative” and “MRD-positive” patient groups, a cutoff of 0.1% is recommended.
7 If true MRD ,0.1% is found, report this as “MRD-positive ,0.1%, may be consistent with residual leukemia.” If applicable, the comment “this level has not
been clinically validated” should be added.
8 In a multicenter setting, transport and storage of full BM at room temperature for a period of 3 d is acceptable.
9 Single-center studies with no extensive experience on MFC MRD are strongly discouraged.
Molecular biology
1 Molecular MRD analysis is indifferent to the anticoagulant used during cell sampling; thus, heparin or EDTA can be used as anticoagulant.
2 Aspirate 5-10 mL BM and use the first pull for molecular MRD assessment.
3 WT1 expression should not be used as an MRD marker unless no other MRD marker is available in the patient.
4 Do not use mutations in FLT3-ITD, FLT3-TKD, NRAS, KRAS, DNMT3A, ASXL1, IDH1, IDH2, or MLL-PTD and expression levels of EVI1 as single MRD
markers. However, these markers may be useful when used in combination with a second MRD marker.
5 We define molecular progression in patients with molecular persistence as an increase of MRD copy numbers $1 log10 between any 2 positive samples.
Absolute copy numbers should be reported in addition to the fold increase to enable the clinician to make his or her own judgments.
6 We define molecular relapse as an increase of the MRD level $1 log10 between 2 positive samples in a patient who previously tested negative. The
conversion of negative to positive MRD in PB or BM should be confirmed 4 wk after the initial sample collection in a second sample from both BM and PB. If
MRD increases in the follow-up samples $1 log10, molecular relapse should be diagnosed.
Clinical
1 Refine morphology-based CR by assessment of MRD, because CRMRD
2 is a new response criterion according to the AML ELN recommendation 2017.
Use MRD to refine risk assessment before consolidation treatment, the postinduction time point closest to consolidation treatment is recommended.
2 MRD monitoring should be considered part of the standard of care for AML patients.
Monitoring beyond 2 years of follow-up should be based on the relapse risk of the patient and decided individually.
Patients withmutantNPM1,RUNX1-RUNX1T1,CBFB-MYH11, orPML-RARA should havemolecular assessment of residual disease at informative clinical time points.
3 Not to assess molecular MRD in subtypes other than APL, CBF AML, and NPM1-mutated AML.
4 For AML patients not included in the molecularly defined subgroups here, MRD should be assessed using MFC.
During the treatment phase, we recommend molecular MRD assessment at minimum at diagnosis, after 2 cycles of standard induction/consolidation
chemotherapy, and after the end of treatment in PB and BM.
During follow-up of patients with PML-RARA, RUNX1-RUNX1T1, CBFB- MYH11, mutated NPM1, and other molecular markers we recommend molecular
MRD assessment every 3 mo for 24 mo after the end of treatment in BM and in PB. Alternatively, PB may be assessed every 4-6 wk.
5 Failure to achieve an MRD-negative CR or rising MRD levels during or after therapy are associated with disease relapse and inferior outcomes and should
prompt consideration of changes in therapy.
6 In APL, the most important MRD end point is achievement of PCR-negativity for PML-RARA at the end of consolidation treatment.
For patients with PML-RARA fusion and low-/intermediate-risk Sanz score who are treated with ATO and ATRA, MRD analysis should be continued until the
patient is in CRMRD
2 in BM and then should be terminated.
7 Detectable levels of PML-RARA by PCR during active treatment of APL should not change the treatment plan for an individual patient.
8 A change in status ofPML-RARA by PCR from undetectable to detectable, and confirmed by a repeat sample, should be regarded as an imminent disease relapse in APL.
9 Patients with CBF AML should have an initial assessment of MRD after 2 cycles of chemotherapy, followed by serial measurements every 3 mo for at least the
first 2 y after the end of treatment.
10 MRD should be assessed pretransplant.
11 MRD should be performed posttransplant.
12 All clinical trials should require molecular and/or MFC assessment of MRD at all times of evaluation of response.
Reprinted from Schuurhuis et al.24
ATO, arsenic trioxide; ATRA, all-trans retinoic acid; BM, bone marrow; HLA-DR, HLA–antigen D related; PB, peripheral blood.
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death22 and of outcomes of allo-HSCT.31,32 Another study using
whole-genome or exome sequencing of samples from a cohort of
adults with AML found that detection of persistent leukemia-
associated mutations in bone marrow cells during remission
;30 days after start of chemotherapy was linked to a significantly
increased risk of relapse, shorter event-free survival (EFS), and
poorer OS.33
Thus, adding MRD evaluation to other posttreatment assessments
(eg, morphologic evaluations) could help guide postremission
treatment strategies by identifying patients at high risk of relapse
who might benefit from preemptive therapy,34 an appealing
treatment concept that will require formal validation. Although not
proven to date, the concept of MRD eradication aiding decision-
making and improving outcomes of patients with AML is plausible.
This is supported by experience with bispecific antibodies such as
blinatumomab in ALL.35
This review examines current methods of MRD detection, some
challenges in adopting MRD testing in routine clinical practice, and
describes some of the recent recommendations from the ELN MRD
Working Party consensus statement for the detection of MRD in
AML.24
MRD detection methods
Technologies to measure MRD based on immunophenotype,
cytogenetic abnormalities, and molecular mutations each have
advantages and disadvantages. The clinical usefulness of MRD
detection depends on the choice of MRD marker (eg, specific gene
mutation, surface antigen), which in some cases might be a therapeu-
tic target.19,36 An ideal MRD test should discriminate between cells
that would not cause relapse from the smallest clinically significant
populations of leukemic cells that hold the potential to cause relapse.37
Current MRD testing methods have not achieved this ideal state,
except for PCR testing in APL.38 Table 3 summarizes the advantages
and limitations of available methods of MRD detection. MFC and
RT quantitative PCR (RT-qPCR) are the most commonly used
technologies; more recently, next-generation sequencing (NGS) is
being used for molecular assessments.6,7,23,37,39,40 Fluorescence
in situ hybridization or chromosome banding analysis can detect
leukemic cells with cytogenetic abnormalities41 but, because a
smaller number of cells are interrogated, are generally less sensitive
than MFC or molecular methods. Table 4 lists potential markers for
monitoring MRD in AML and the testing technologies used to detect
them.15,24,42
MFC
MFC uses panels of fluorochrome-labeled monoclonal antibodies to
identify aberrantly expressed antigens located on (or within)
leukemic cells.15 Instruments that have multiple lasers to detect
different fluorochromes, with combinations of multiple monoclonal
antibodies, have increased the sensitivity of MFC to detect 1023 to
1025 leukemic cells within the white blood cell compartment.43
There are 2 main approaches used to detect MRD by MFC; 1
involves identification of leukemia-associated immunophenotypes
(LAIPs) that differ from the majority of normal hematopoietic cells
and the other approach entails identification of different-from-
normal (DfN) patterns.44 LAIP are cells with abnormal patterns of
antigens; examples include cross-lineage antigen expression (eg,
expression of lymphoid markers in myeloid blasts), asynchronous
antigen expression (eg, coexpression of antigens that are not
usually found together during normal cellular differentiation), and
over- or underexpression of antigens compared with normal
levels.45-47 An extensive panel of monoclonal antibodies is required
to detect all potentially abnormal LAIP antigen expression patterns
in AML, which can number up to 100.26 A standard fixed
monoclonal antibody panel is used to identify DfN patterns at all
stages of disease/treatment with MFC.44 An advantage of this
method is that it does not restrict MRD determination to specific
LAIP present at diagnosis and takes immunophenotypic shifts over
time into account.44 LAIP detection by MFC is more commonly
used than the fixed-antibody method,42 but differences between the
LAIP and DfN approaches may be minimized if sufficiently large
antibody panels ($8 colors) are used for detection.24 Because
phenotypes may change over time by gaining or losing specific
abnormalities or patterns of abnormalities during disease evolution,
a prior MRD target (as defined by a specific LAIP) may be less
useful at later time points for the same patient.15,37,48 Therefore, the
ELN MRD Working Party suggests using a “LAIP-based DfN
approach” to monitoring MRD (ie, using the same antibody-
fluorochrome combinations with a minimum set of markers during
follow-up assessments as those used at diagnosis to track
emerging aberrancies) (Table 2).24 Researchers continue to work
on improving MFC methodology and technology. For example, 1
group has developed a 1-tube assay with a single fluorescence
channel that appears to work as well as standard 7-tube antibody
panel to accurately quantify CD341CD382 leukemic stem cells.49
RT-qPCR
RT-qPCR is used to amplify leukemia-associated genetic abnor-
malities. Optimized RT-qPCR assays are more sensitive than MFC,
with a detection range of 1024 to 1026.24,43 Additionally,
quantitative assays that measure number of leukemic transcripts
can be informative of whether transcript levels are rising or falling
and can potentially inform further therapy, although benefits of
MRD-directed therapy in AML are not yet firmly established.44
Viable targets for molecular MRD monitoring include leukemic
fusion genes such as promyelocytic leukemia gene retinoic acid
receptor-a (PML-RARA), core-binding factor subunit b myosin
heavy chain 11 (CBFB-MYH11), and runt-related transcription
factor 1 (RUNX1)/RUNX1 translocated to 1 (RUNX1T1), and
mutant NPM1.24 Wilms’ tumor gene (WT1) should not be used as
an MRDmarker because of poor sensitivity and specificity unless no
other MRD markers are available.24 The ELN MRD Working Party
recommends against use of Fms-like tyrosine kinase internal
tandem duplication (FLT3-ITD), FLT3-TKD, NRAS, KRAS, IDH1,
IDH2,MLL-PTD, and expression levels of EVI1 as single markers of
MRD because they are prone to frequent losses or gains; however,
these mutations may have prognostic significance if accompanied
by other MRD markers.24 Given available molecular targets,
RT-qPCR assessment of MRD is thought to be applicable to only
;50% of all AML cases and less than ;35% in older patients
(Figure 1), whereas MFC can detect MRD in ;90% of patients
when a comprehensive antibody panel is used.19,28,44,46,47,50
Limitations of RT-qPCR–based MRD assays are their depen-
dence on specific mutations, requiring individual reference standard
curves based on target serial dilutions.51 Digital PCR, a high-
throughput technology that generates absolute quantification, can
clonally amplify target nucleic acids and does not require a
reference standard curve, has greater assay sensitivity than
RT-qPCR.52 For example, digital PCR can detect a variety of
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NPM1 mutation subtypes without the need for multiple plasmid
standards.53,54
NGS
Next-generation DNA sequencing technologies, which allow
parallel and repeated sequencing of millions of small DNA
fragments, can be used to evaluate a few genes or an entire
genome.55 The ability of NGS to assay large numbers of mutated
genes could help trace the evolution of malignant clones, which
cannot be done with RT-qPCR.15 Studies have demonstrated the
feasibility of NGS to monitor mutations for which targeted therapies
are available, such as FLT3-ITD56 and IDH1/2,57 and mutations
with prognostic relevance, such as CEBPA and NPM1 in patients
with AML.10 A recent study compared a targeted 28-gene NGS
panel for detection of common AML mutations (with variant allele
frequency [VAF]$5%) and a 10-color MFC assay of different-from-
normal MRD in patients with AML before allo-HSCT.58 Results
of the 2 assays were concordant in 71% of patients. For patients
in CR or CR with incomplete hematologic recovery (CRi), MRD
measured by NGS was much greater than the estimated
percentage of aberrant blasts detected by MFC, suggesting that
residual mutations persisted in non-blast compartments during
remission. Patients found to be MRD-positive with both assays had
the highest risk of relapse compared with patients who were
negative by both assays and with patients who had discordant
assay results.58 Similarly, in 340 patients with AML in CR or CR with
CRi, there was a 69.1% concordance of MRD detection in the bone
marrow using a 54-gene NGS evaluation and an MFC assay;
Table 3. Pros and cons of methods used to detect MRD in AML
Technology Sensitivity Pros Cons
MFC ;1024 to 1025 Wide applicability (.90%) Challenging and somewhat subjective interpretation
requires experienced pathologist
Relatively quick (results #1 d) Sensitivity dependent on antibody panel used
Single result interpretable Limited harmonization and standardization across
laboratories
High specificity when using defined LAIP Leukemic phenotype not necessarily stable over time
(eg, initial LAIP may not identify subclones leading
to relapse)
Can detect cells with leukemia-stem cell phenotype
Can distinguish between live and dead cells
Ease of data storage
Provides information about whole sample cellularity
NGS ;1023 to 1025 Relatively easy to perform Limited standardization
Sensitive Error rate leads to low sensitivity of mutated
sequences
Applicable to specific subgroups Mutated genes can be detected in healthy people
without hematologic abnormalities
Persistence of some genetic abnormalities in patients
in long-term remission
Risk of contamination
RT-qPCR ;1023 to 1025 Wide applicability Results may take multiple days
May be run by any certified laboratory with RT-qPCR
capacity
Expensive (computationally demanding and time-
consuming)
High sensitivity ($MFC) Requires high-level expertise
Well standardized Requires setting of threshold limits
Quality assurance routinely incorporated Interpretation often requires trend of results
Different mutations have different biological
consequences in AML
Molecular targets applicable to only;50% of all AML
cases and ,35% in older patents
FISH ;1 to 1022 Superior to PCR-based assays for detection of
numeric cytogenetic abnormalities (gains and
losses of whole chromosomes or deletions/
duplications)
Considerably less sensitive than PCR or MFC
Not useful for patients with normal karyotype
Quality-assured probes are expensive; technique is
labor intensive
Chromosome banding analysis NA More common in routine clinical practice Labor-intensive, comparatively costly, low-throughput
technique reliant on highly trained technical staff
Evaluates the dividing proportion of cells ;103 less sensitive than FISH
Not useful for patients with normal karyotype
FISH, fluorescence in situ hybridization; NA, not available. QA, quality assurance.
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however, persistent mutations were detected by NGS only in 64
patients.23 Four-year relapse rate was highest among patients with
MRD detected by both methods (73.3%), followed by those with
MRD only on NGS (52.3%), those with MRD only on MFC (49.8%),
and those who were MRD-negative on both assays (26.7%).23
Factors that complicate the use of NGS to monitor MRD in patients
with AML include the genetic clonal heterogeneity at AML diagnosis
and during the course of the disease. The predominant leukemic
clone at presentation might not be the clone that causes clinical
relapse and mortality.59 Moreover, determination of clonality in a
given sample can be influenced by the depth of sequencing
and the algorithm used to identify mutations.37 NGS currently
has an intrinsic error rate that limits its sensitivity for most single-
nucleotide variants to ;1% to 2% of all reads.15 NGS typically
generates shorter sequence lengths; for example, 1 of the most
commonly used technologies, Illumina’s sequencing by synthe-
sis, routinely produces read lengths of 75 to 100 base pairs from
libraries with insert sizes of 200 to 500 base pairs. Thus,
assembly of longer repeats and duplications may suffer from the
short read length.60 Further, NGS technology is computationally
demanding, time-consuming, and still expensive (although it is
expected that costs may drop in the future), which might make it
difficult to apply in clinical practice. Reflecting the current state
of development, the ELN MRD Working Party suggests NGS
techniques for MRD measurement are best reserved for clinical
trials at this time.24
Challenges to clinical application of
MRD testing
AML is genetically diverse and, currently, there is no uniform
approach to detecting the leukemic cells that are biologically
capable of and likely to cause relapse.37 The genetic heterogeneity
of AML and lack of universal antigenic surface markers on leukemic
stem cells increase the challenge of standardizing MRD detection
protocols. Additional challenges to adopting MRD testing in routine
clinical practice for patients with AML have included the absence of
interlaboratory standardization or consensus regarding optimal key
parameters, including type of specimen, MRD target, timing of MRD
assessment, technology (eg, MFC vs RT-qPCR), testing protocols,
and lack of established cutoff values,42,61 although the ELN MRD
Working Party recommendations address several of these issues.24
Variables that affect the ability to detect MRD are assay sensitivity,
the skills and expertise of personnel, biologic properties of the
leukemic cells, and the quality and number of viable cells used for
analyses.15,36,37 The ELN 2017 Recommendations for Diagnosis
and Treatment of AML highlight that MRD testing should be
performed in experienced, centralized diagnostic laboratories.
Because sensitivities vary by type of MRD marker and testing
method, reported results should specify the test applied, assay
sensitivity, and cutoff values.10 Currently, the National Comprehen-
sive Cancer Network AML 2018 Clinical Practice Guidelines for
Table 4. Testing technologies and potential markers for monitoring
MRD in AML
Testing technologies Potential markers
MFC CD2 CD34
CD4 CD45
CD7 CD56
CD13 CD123
CD15 CD117
CD19 HLA-DR
CD33
NGS NPM1
RUNX1
FLT3-ITD
IDH1/IDH2
RT-qPCR CBFB/MYH11
FLT3-ITD
IDH1/IDH2
NPM1
RUNX1/RUNX1T1
t(10;11) – KMT2A-MLLT10
t(11;19) – KMT2A-ELL or KMT2A-MLLT1
t(6;11) – KMT2A-MLLT4
t(9;11) – KMT2A-MLLT3
WT1
MLL/MLLT3, mixed lineage leukemia.
2%
7%
42%
11%
12%
6%
30%
38%
13%
7%
5% 23%
68%
13%
2%
1%
4%
t(15;17)/PML-RARA0-15 15-60 >60
t(8;21)/RUNX1-RUNX1T1
inv(16)/CBFB-MYH11
11q23/MLL fusions
t(6;9)/DEK-CAN
NUP98-NSD1
CBFA2T3-GLIS2
NPM1 mutant
Other rare fusions
No recurring leukemia-
specific marker
1%
1%
1% 1%
1% 1% 2%
4%
4%
Figure 1. Proportions of leukemia-specific MRD targets detectable by RT-qPCR for patients with AML by age group. Reprinted from Grimwade and Freeman.19
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AML do not recommend MRD monitoring, but note that ongoing
research is moving MRD monitoring to the forefront for all patients
with AML.6
Another subject of debate is whether routine clinical sampling for
MRD testing should be performed on peripheral blood or bone
marrow. The ELN MRD consensus report recommends testing
both bone marrow and blood for molecular MRD during treatment.24
Bone marrow sampling generally offers greater sensitivity because
MRD levels in peripheral blood are lower than in bone marrow.19
Nevertheless, peripheral blood sampling is less expensive and less
painful for patients who may be unwilling to undergo the more
frequent bone marrow sampling required to monitor MRD during
various courses of treatment.14 MRD analysis of peripheral blood
requires a minimum of 20 mL of blood; in patients with white blood
cell counts ,1 3 109/L, more blood may be necessary to improve
sensitivity.24 The ELN MRD Working Party suggests aspirating 5 to
10 mL of bone marrow using the first pull, noting that contamination
from peripheral blood increases as bone marrow sample volume
increases.24 Additionally, peripheral blood may be preferable for
PCR-based gene expression MRD monitoring because of high
background “noise” in bone marrow.14 A study of younger adults
(ages 18-60 years) with AML found that as detected by RT-qPCR,
the presence of mutant NPM1 MRD in peripheral blood in first
remission was a strong predictor of relapse, independent of
cytogenetics and FLT3-ITD status, and might have application in
selecting patients who would benefit from allo-HSCT.32
The choice of an MRD target can be confounded by the persistence
of genetic abnormalities in patients in long-term remission.62 For
example, mutated DNMT3A with up to 50% VAF can persist in
patients who have been in remission for several years.62 Another
concern is that some commonly mutated genes in AML, such as
TET2,DNMT3A, and ASXL1, can also be mutated in healthy people
with no hematologic abnormalities, especially as people age. This
phenomenon has been called age-related clonal hematopoiesis of
indeterminate potential. Whole exome sequencing of samples from
12 380 people with no hematologic malignancies indicated 10% of
persons age.65 years showed evidence of clonal hematopiesis.63
These mutations in older patients with AML may not be the drivers
of leukemogenesis.63-65 However, the presence of AML-associated
mutations may be indicative of early events in the development of
hematologic malignancies in some cases because they significantly
increase the risk of eventually developing one.65,66
In a recent study, samples from 430 patients with AML in CR or CRi
who had at least 1 mutation at diagnosis were obtained between 21
days and 4 months from the start of a second treatment cycle for
analysis by targeted NGS and by MFC.23 Mutations in TET2,
DNMT3A, and ASXL1 (DTA) were present during remission in
.50% of patients. Detection of DTA mutations was not associated
with a higher 4-year relapse rate than that of patients without these
mutations unless they were accompanied by other non-DTA
mutations.23 The researchers speculated that DTA mutations may
have persisted in nonleukemic clones that repopulated the bone
marrow after induction chemotherapy.23
A study of patients with de novo AML who had received up to 2
rounds of induction chemotherapy evaluated MRD status at 30
days after treatment using digital sequencing of leukemia-specific
mutations in 50 patients in morphologic remission.33 Although all
patients showed normal morphology at day 30, some patients’
samples showed clearance of all mutations; others showed
clearance of only a few of the mutations, which returned at
relapse; a third group of patients showed clearance in a subset
of the mutations at day 30, but the founding clone mutations
persisted in almost every cell.33 Patients with EFS durations.12
months were significantly less likely to have persistent disease as
indicated by VAF at day 30 than those with EFS #12 months
(P 5 .01); for patients who relapsed, day 30 VAF had increased
because cells containing those mutations reexpanded.33 These
data suggest MRD testing at 30 days posttreatment can provide
more important prognostic information than morphologic status,
but repeated testing and trends in MRD status over time may be
more informative.37 The optimum interval duration for sequential
MRD testing is unknown and may depend on disease charac-
teristics. To avoid false-positive results, some have suggested
that a confirmatory MRD test should be performed at 2 to 4
weeks after a positive MRD test before making predictions
about impending relapse.37
The optimal time for MRD testing may depend on the type of MRD.
Ommen and colleagues showed the kinetics of molecular relapse
can differ markedly among leukemias characterized byNPM1, PML-
RARA, RUNX1-RUNX1T1, and CBFB-MYH11 AML.67 The inves-
tigators developed a model to predict the time between molecular
relapse and hematologic relapse. They found that CBFB-MYH11
AML displayed a slower clone regrowth than AML with the other
molecular signatures and recommended MRD testing for CBFB-
MYH11 be performed every 6 months, whereas testing for PML-
RARA MRD was recommended for every 2 months.67 There is
a continued need to establish the optimal intervals for MRD
assessment to predict impending relapse. Currently, the ELN MRD
Working Party recommends MRD testing at diagnosis, after 2
cycles of chemotherapy at the closest time point before consoli-
dation treatment, and during follow-up of patients with PML-RARA,
RUNX1-RUNX1T1, CBFB-MYH11, mutated NPM1, and other
molecular markers. Molecular MRD assessment should be con-
ducted in bone marrow and peripheral blood every 3 months for
24 months after the end of treatment, or in peripheral blood every
4 to 6 weeks.24 MRD testing should be performed before and after
bone marrow transplant.24
More studies are also needed to determine relevant MRD
thresholds, which will of necessity vary according to the technology
used for assessment and the type of tissue under study. In the study
described previously, day 30 samples were assessed for MRD
using digital sequencing that included probes covering all exons of
264 recurrently mutated genes in AML.33 The VAF threshold was
set at 2.5% in bone marrow; investigators noted that because the
vast majority of AML-associated somatic mutations are heterozy-
gous, a 2.5% VAF threshold suggests that at least 5% of bone
marrow cells under examination would contain the mutation(s).33
Indeed, detection of persistent AML-associated mutations in $5%
of cells in day 30 remission samples was significantly associated
with reduced OS and increased risk of relapse compared with
patients who attained mutational clearance.33 Studies measuring
LAIP by MFC use lower detection thresholds, for example, from
0.01% to 1.0%,26 and thresholds may depend on the types of LAIP
under study.28 The ELN MRD Working Party suggests a threshold
of 0.1% to distinguish between MRD positivity and negativity;
however, they noted that MRD LAIP levels ,0.1% may still signal
residual leukemia.24
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The correlation between MRD status and relapse risk has
generated substantial interest in using results of MRD testing to
direct therapy decisions for AML patients; for example, therapy
might be initiated or intensified when MRD is present, reduced, or
discontinued for those who are MRD-negative. Initiating or in-
tensifying treatment of patients with MRD may lessen risk of relapse
and improve OS, although this remains to be proven.14,37 The risks
associated with any therapy must be considered when making
decisions based on MRD status. At present, there are few
published studies that have evaluated MRD stratification and/or
therapeutic strategies to eradicate MRD in patients with AML.
Azacitidine has been shown to increase expression of epigenetically
silenced leukemia antigens and induce a CD81 T-cell response
to tumor antigens posttransplant, potentially augmenting a graft-
versus-leukemia effect.68-71 At least 2 studies have evaluated
preemptive use of azacitidine after SCT based on detection of
MRD. The RELAZA phase 2 study evaluated azacitidine after allo-
HSCT in 20 patients with CD341 AML or myelodysplastic syndromes
and signs of MRD, defined as decreases of peripheral blood
CD341 donor chimerism to ,80%, without concomitant signs of
hematologic relapse.72 After 4 cycles of azacitidine, 10 patients
(80%) were MRD-negative; of these, 4 remained MRD-negative at
a median follow-up of 347 days. The investigators noted that
tracking MRD after allo-HSCT via peripheral blood CD341 donor
chimerism monitoring allowed preemptive use of azacitidine
only when MRD was detected, avoiding unnecessary toxicity
in patients in CR at low risk of relapse.72 In another study,
10 patients with mutant NPM1 AML and normal karyotype in first
or second CR after intensive chemotherapy or autologous or
allo-HSCT who showed evidence of molecular relapse (defined
as a 1% increase in mutant NPM1 transcripts in bone marrow) or
persistent MRD in sequential RT-PCR analyses of bone marrow
or peripheral blood received azacitidine treatment.73 Molecular
response was defined as a 1-log reduction in MRD from the
pretreatment value. At a median follow-up of 10 months (range,
2-12), patients had received a median of 5 azacitidine treatment
cycles. Of the 10 patients, 7 showed a molecular response and
remained in CR.73
On a promising note, because of growing acceptance of the
prognostic value of MRD, several ongoing AML studies are pro-
spectively evaluating the effect of interventions onMRD. Some of these
studies require detectable MRD as an eligibility criterion.
Conclusions
The ELN MRD Working Party recommends MRD testing as part
of the standard of care for AML patients.24 Its recently published
guidelines promote widespread adoption of MRD testing for
monitoring of therapeutic efficacy and/or the prognoses of
patients with AML; however, some questions remain. The MRD
Working Party notes that the predictive power of several
mutations is low or needs to be clarified. They recommend further
study of the clinical implications of detectable flow cytometric
MRD levels ,0.1%. Moreover, different MRD thresholds after
induction chemotherapy may have variable meaning in differing
patient risk groups and the clinical significance of MRD for patients
treated with nonintensive therapies such as hypomethylating agents
requires more study.24,74 Ultimately, the molecular heterogeneity of
AML and clonal architecture may prevent a “1-size-fits-all” approach
to MRD detection.19 Incorporation of MRD as an end point of
ongoing and future randomized clinical trials should provide the
data needed to move toward improved understanding of the
influence of MRD markers in patients not included in molecularly
defined AML subgroups (eg, APL, CBF-AML, AML with BCR-
ABL1, AML with NPM1 mutations). These studies will also help
determine whether MRD assessment will prove to be a more
accurate measure of therapeutic efficacy than current morphologic
measures.
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